BILL ANALYSIS
HR161
BULLISHNew Source Review Permitting Improvement Act
HR161 (New Source Review Permitting Improvement Act) has been assessed with a bullish outlook for investors. This legislation directly affects Chevron ($CVX), $DD, $DOW and $LYB and 3 other tickers. The primary sectors impacted are Energy, Materials and Utilities. View the full bill text on Congress.gov.
bullish
Market Sentiment
7
Affected Stocks
3
Sectors Impacted
Key Takeaways for Investors
HR161 reported out of House Energy & Commerce Committee on April 28, 2026; now on House Union Calendar awaiting floor vote.
Refiners ($MPC, $PSX) are the primary beneficiaries with 7-day gains of +9.37% and +8.75% respectively, reflecting market pricing of regulatory relief.
The bill redefines NSR 'modification' using a 10-year peak-hourly emission baseline and exempts reliability/safety projects — directly reducing permitting delays and compliance costs.
Chemical companies ($LYB, $DOW) show moderate gains (+4.58%, +2.51% weekly), while specialty chemicals ($DD, $CE) show minimal or negative movement, indicating market differentiation.
No funding authorized; impact is purely deregulatory. Forward passage probability is moderate given partisan committee split (28-23) and no Senate companion bill.
How HR161 Affects the Market
Refining sector stocks are already pricing in regulatory relief, with Marathon Petroleum ($MPC) at $241.81 and Phillips 66 ($PSX) at $173.49 after strong 7-day gains. The divergence from chemical stocks (DuPont down -3.48%, Celanese flat) indicates the market is correctly differentiating: refiners are the pure-play beneficiaries with the highest NSR exposure. Chemical companies have secondary benefit but their 30-day trends remain negative (LYB -9.3%, DOW -4.85%, PSX -6.13%), suggesting macro headwinds (lower product demand, higher feedstock costs) are still weighing on the sector despite the regulatory catalyst. For investors: MPC and PSX have the highest sensitivity to NSR relief given their U.S. refining focus. XOM and CVX offer diversified exposure but have less share price upside from this bill alone. The absence of a Senate companion bill introduces execution risk — if the bill dies in the 119th Congress without passage, some of the recent price gains could retrace. Conversely, if the bill is enacted, MPC and PSX could see further multiple expansion as compliance cost savings are reflected in earnings estimates. The market data from April 28-30 already shows aggressive buying, suggesting institutional positioning for floor passage.
Bill Details
| Metric | Value |
|---|---|
| Bill Number | HR161 |
| Market Sentiment | bullish |
| Event Date | |
| Affected Sectors | Energy, Materials, Utilities |
| Affected Stocks | Chevron ($CVX), $DD, $DOW, $LYB, Marathon Petroleum ($MPC), Phillips 66 ($PSX), Exxon Mobil ($XOM) |
| Source | View on Congress.gov → |
Summary
HR161 (New Source Review Permitting Improvement Act) reported out of House Energy & Commerce Committee on April 28, 2026. Refiners ($MPC, $PSX) and chemical companies ($LYB, $DOW) show strong 7-day gains of +9.37% and +8.75% respectively, reflecting market pricing of regulatory relief. The bill redefines NSR 'modification' to require a 10-year peak-hourly baseline and exempts reliability/safety projects, directly lowering compliance costs for heavy industry.